about
Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C.Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotypeSensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosidesResveratrol Co-Treatment Attenuates the Effects of HIV Protease Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial Respiration.Availability of data on adverse reactions to antiretroviral drugs in medical charts according to the Naranjo algorithm: an example of a Brazilian historical cohort.In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitorsNeurological and psychiatric adverse effects of antiretroviral drugs.In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.Antiretroviral therapy-associated acute motor and sensory axonal neuropathyEvaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathyMitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrugThe Relationship Between HIV Infection and Cardiovascular Disease.Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus.Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors.Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in AccraPremature and accelerated aging: HIV or HAART?Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.The impact of diabetes on CD4 recovery in persons with HIV in an urban clinic in the United States.Aspartic acid based nucleoside phosphoramidate prodrugs as potent inhibitors of hepatitis C virus replication.Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementiaInteraction of 2'-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma.An unusual case of hyperlactataemia in a neonate.Blood-based bioenergetic profiling: A readout of systemic bioenergetic capacity that is related to differences in body composition.Lactic acidosis and abnormal liver function in advanced HIV disease.Lipodystrophy among HIV-Infected Patients Attending Care and Treatment Clinics in Dar es Salaam.Select HIV protease inhibitors alter bone and fat metabolism ex vivo.Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.Human immunodeficiency virus genotype and hypertriglyceridemia.Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells.First-line therapy and mitochondrial damage: different nucleosides, different findings.Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients.
P2860
Q24804388-315ED233-30DA-4C12-B902-ECEF03A1C6A1Q28344599-6B3C3E77-28AC-4627-AFD7-095D6B68F48AQ28485227-86FC9626-6737-4C98-A5BA-964783FB1820Q30397743-B99AF8B9-6954-4588-8551-53AD76FEA158Q30795747-7BA6BC1E-E697-4B69-A22F-3257BBEFC4C5Q30885827-C1C4CC77-D65B-44D8-959F-07CA0AC3A6CDQ33447663-67C88541-C49D-4D1D-B615-CA66741A24CEQ33904479-E0204D72-4EF4-4B5C-A428-B77E2CD935E7Q34039419-D9F91802-763F-4618-9C8F-A18FF967F408Q34289964-10BA384E-1183-4F24-BA45-9849853F5394Q34352006-BD16874F-954A-47DC-A924-3EDC675F1308Q34569959-96F16887-CBC1-42E1-B551-EC5BB7EB46A7Q34932672-1E2FEB58-0D55-4442-95CD-AD26F7A243CEQ35879021-F2FF718C-A675-412E-88D3-8D89C2189A4DQ36255314-85AD7AA3-D6D7-4543-9770-DEEA5799B452Q36425068-1D425D29-843D-4FCA-B91E-C885FF829888Q36441623-4E0C766A-2F61-409F-8D32-B76BB7AFA45AQ37247699-0A55BB46-8DDA-4DBC-B8DB-591D41FFF2D8Q37429096-2B621AB3-F0BC-47D4-AC7A-A3360F5564C2Q37798546-14CB4A92-9BF4-4FFC-BBB5-90D85BBE87E2Q38367690-A7B5F13E-98AB-48D3-8EA1-8B95915812BCQ38568978-F404D9AE-8CD7-4C74-B85A-4A9C9F2A3AADQ39034736-51A1A541-5564-4756-BFB6-FD89AEC462A4Q39244930-4976761B-0571-4805-8B09-2F4EFDD0ECF9Q39474417-56DE3A16-F7F5-4D96-8359-714BE9CA48A5Q39918902-A9FF1EFC-1A1F-4624-92AF-50FC68644B0CQ40482204-C7CFB03C-C21B-488F-8D14-4890AB5CB4C8Q41106565-025C8A51-C84E-47DE-9DF8-E3ED9A7E6DD1Q41862645-54C5B40C-7382-4317-8C6B-0669EC87D93DQ42167760-379C43BF-2757-4B3D-AC52-BE53ABBCAC54Q42250152-8A42C20B-4972-4EE7-8E9C-E78121915DE2Q42331828-092A8D46-6C9D-45E4-AA89-B59A43D491E3Q43062057-B1451051-77EE-41A5-8226-E2E033A9D31FQ43923867-DF60C5B3-4309-4B0F-BD8F-03C25E55704EQ43950615-76F829FD-4F9E-41F8-AF2A-7729C24608D4Q44003033-AD9F9A22-9DBD-40BE-BFD8-0EAD7BA59CF0Q44060430-ED3A01D0-D7EA-457D-B6CA-93B3C75D4FBBQ44297096-6C3CB71E-6E42-4770-BFB1-9DAA4833A87EQ44309069-9508DAAF-CF52-49C6-8FC7-B4EB16AA1C1BQ45060359-38D58FB9-A0BB-42FB-AD90-CDDD7ACDC72A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Mitochondrial toxicity and HIV therapy.
@ast
Mitochondrial toxicity and HIV therapy.
@en
Mitochondrial toxicity and HIV therapy.
@nl
type
label
Mitochondrial toxicity and HIV therapy.
@ast
Mitochondrial toxicity and HIV therapy.
@en
Mitochondrial toxicity and HIV therapy.
@nl
prefLabel
Mitochondrial toxicity and HIV therapy.
@ast
Mitochondrial toxicity and HIV therapy.
@en
Mitochondrial toxicity and HIV therapy.
@nl
P2860
P356
P1476
Mitochondrial toxicity and HIV therapy.
@en
P2093
P2860
P304
P356
10.1136/STI.77.3.158
P577
2001-06-01T00:00:00Z